Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis by Gan, I.M. et al.
doi:10.1136/bjo.85.11.1289 
 2001;85;1289-1293 Br. J. Ophthalmol.
  
Meurs 
Ivan M Gan, Jaap T van Dissel, W Houdijn Beekhuis, Wouter Swart and Jan C van
  
 endophthalmitis
concentrations in patients with postoperative 
Intravitreal vancomycin and gentamicin
 http://bjo.bmj.com/cgi/content/full/85/11/1289
Updated information and services can be found at: 
 These include:
 References
 http://bjo.bmj.com/cgi/content/full/85/11/1289#otherarticles
1 online articles that cite this article can be accessed at: 
  
 http://bjo.bmj.com/cgi/content/full/85/11/1289#BIBL
This article cites 23 articles, 5 of which can be accessed free at: 
Rapid responses
 http://bjo.bmj.com/cgi/eletter-submit/85/11/1289
You can respond to this article at: 
 service
Email alerting
top right corner of the article 
Receive free email alerts when new articles cite this article - sign up in the box at the
 Notes   
 http://www.bmjjournals.com/cgi/reprintform
To order reprints of this article go to: 
 http://www.bmjjournals.com/subscriptions/
 go to: British Journal of OphthalmologyTo subscribe to 
 on 20 November 2006 bjo.bmj.comDownloaded from 
Intravitreal vancomycin and gentamicin
concentrations in patients with postoperative
endophthalmitis
Ivan M Gan, Jaap T van Dissel, W Houdijn Beekhuis, Wouter Swart, Jan C van Meurs
Abstract
Background/aims—To study the intravit-
real antibiotic concentrations and the eY-
cacy of an intravitreal dosing regimen to
treat patients with postoperative bacterial
endophthalmitis. This regimen, based on
pharmacokinetic/pharmacodynamic con-
siderations, relies on a repeat antibiotic
injection of a lower dose than is generally
used.
Methods—In consecutive patients with
suspected postoperative endophthalmitis
a vitreous biopsy for bacterial culture was
taken before 0.2 mg vancomycin and
0.05 mg gentamicin were injected intravit-
really. After 3 or 4 days a second biopsy
was taken for bacteriological culture and
to measure intravitreal vancomycin and
gentamicin concentrations, followed by a
repeat injection of 0.2 mg vancomycin.
Results—17 patients entered the study. In
11 patients the initial bacterial culture was
positive, predominantly coagulase nega-
tive staphylococci. All second vitreous
biopsies were sterile. Intravitreal vanco-
mycin levels varied between 2.6 and 18.0
µg/ml (mean 10.3 (SD 4.1) µg/ml) after
3 days and between 3.1 and 16.6 µg/ml
(mean 7.5 (6.2) µg/ml) after 4 days which is
well above the minimal inhibitory concen-
tration for most micro-organisms. Con-
centrations of intravitreal gentamicin
varied between 0.90 and 3.3 µg/ml (mean
1.6 (0.72) µg/ml) after 3 days and between
1.2 and 2.6 µg/ml (mean 1.9 (0.99) µg/ml)
after 4 days.
Conclusion—This dosing regimen re-
sulted both in adequate intravitreal van-
comycin and gentamicin levels for over a
week as well as in negative second cul-
tures. This study also provides new infor-
mation on intravitreal vancomycin and
gentamicin concentration over time in
patients with postoperative endoph-
thalmitis.
(Br J Ophthalmol 2001;85:1289–1293)
Bacterial endophthalmitis is a severe complica-
tion of intraocular surgery that may rapidly
cause permanent visual loss. Therefore, when
confronted with a possible postoperative infec-
tion of the eye, timely diagnostic and empirical
therapeutic decisions should be made by medi-
cal history taking and a focused examination
without the aid of the results of laboratory and
culture results. If it is likely that the symptoms
and signs are due to bacterial infection, prompt
antimicrobial treatment is indicated.
In empirical therapy, the activity spectrum of
the antibiotic should cover all likely causative
micro-organisms. Other important parameters
directing the choice and dosing regimen of
antibiotics in endophthalmitis include the abil-
ity to achieve eVective concentrations of the
drug inside the eye, especially the vitreous, and
the toxicity of the drug for retinal structures.
The vast majority of postoperative eye infec-
tions are caused by Gram positive bacteria
such as coagulase negative staphylococci, S
aureus, and streptococci.1–3 Awaiting culture
results and susceptibility testing, the methicil-
lin resistance of many strains of staphylococci
make glycopeptides such as vancomycin the
antibiotic of choice.1 3–6 As the penetration of
this drug into non-vitrectomised, inflamed eyes
after intravenous administration is unreliable,
direct intravitreal injection of vancomycin is
recommended.7 8 The eYcacy of such an
empirical antibiotic regimen of vancomycin
injected intravitreally was confirmed in the
Endophthalmitis Vitrectomy Study.1
Thus, the intravitreal injection of vancomy-
cin, supplemented with a second antibiotic
such as ceftazidime or an aminoglycoside cov-
ering for rare Gram negative bacteria, has
become the standard treatment in postopera-
tive endophthalmitis. The commonly recom-
mended 1 mg vancomycin dose, however, is
extremely high as it results in vitreous concen-
trations many times higher than accepted
serum and fluid concentrations of this drug in
severe extraocular infections such as endocar-
ditis and meningitis. Moreover, in some case
reports where vancomycin is used in combina-
tion with amikacin retinotoxicity cannot be
ruled out.9 10
When the antimicrobial eVect of an anti-
biotic depends mainly on how long the
concentration exceeds the minimal inhibitory
concentration (MIC) rather than how high a
dose is given, as is the case for vancomycin,
eYcacious therapy requires more frequent
rather than higher dosages.11 12 To ensure
prolonged exposure of micro-organisms to
vancomycin at a concentration well above the
MIC but without the need for very high and
potential toxic dosing, we decided on a
treatment protocol for suspected postoperative
endophthalmitis consisting of an intravitreal
injection of vancomycin at a dose of 0.2 mg, to
be repeated once after 3–4 days. Initial
treatment included an intravitreal injection of
gentamicin to cover for the rare occurrence of
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Gram negative bacteria. Specimens of the
vitreous for Gram stain and culture were
collected before the start of antibiotic therapy
and at the time of the repeat injection. This
enabled us to prospectively measure concen-
trations of vancomycin and gentamicin in the
vitreous specimens taken at the time of the
repeat injection to investigate whether anti-
biotic levels were adequate and to obtain new
data on the vitreous concentration of these
antibiotics over time.
Materials and methods
The study was performed at the Rotterdam
Eye Hospital, a secondary and tertiary referral
eye hospital. Consecutive patients who had
been referred to the emergency department
because of suspected postoperative endoph-
thalmitis were enrolled over a 10 month
period. Symptoms suggestive of endoph-
thalmitis included a painful and/or red eye,
severe decrease of vision and aqueous cells and
flare with or without hypopyon within 6 weeks
after cataract surgery. According to the guide-
lines of the Endophthalmitis Vitrectomy
Study1 only a vitreous biopsy was performed
with a vitrectome in patients with better than
light perception vision. A core vitrectomy with
anterior chamber infusion was performed in
patients who presented with light perception
only. Undiluted vitreous material was collected
for Gram staining and culture before the start
of antibiotic therapy; the material was cultured
aerobically and anaerobically. At the end of the
procedure all patients received an intravitreal
injection of 0.2 mg vancomycin in 0.1 ml
phosphate buVered saline and 0.05 mg gen-
tamicin in 0.1 ml phosphate buVered saline.
A second intravitreal injection of 0.2 mg
vancomycin was repeated after 3 or 4 days,
preceded by a vitreous biopsy with the
vitrectome for a repeat bacterial culture and
measurements of intravitreal vancomycin lev-
els. Intravitreal gentamicin levels were also
measured when suYcient material had been
obtained.
If the Gram staining or the subsequent
culture of the first biopsy material yielded
Gram negative bacteria, 1 mg ceftazidime was
immediately injected intravitreally followed by
continuous intravenous infusion of ceftazidime
of 6 g per day.
Vitreous levels of vancomycin and gen-
tamicin were determined by fluorescence
polarisation immuno assay (AxSYM, Abbott
Laboratories, Abbott Park, IL, USA).
The study protocol was approved by the
hospital’s medical ethics committee and all
subjects gave permission for the vitreous
sampling for assay of antibiotic concentration
and bacterial culture.
Results
PATIENT CHARACTERISTICS (TABLE 1)
Seventeen consecutive patients entered the
study. The median age was 73 years (range
47–86 years) and there were six men and 11
women. Length of follow up was 3 months.
Seven patients presented with light percep-
tion only vision and underwent a core vitrec-
tomy. In 10 patients with better than light per-
ception only a vitreous biopsy was performed
with a vitrectome. All patients were treated as
intended according to the treatment protocol.
BACTERIOLOGICAL FINDINGS (TABLE 2)
In all patients, vitreous material for Gram stain
and culture was obtained before the adminis-
tration of antibiotics. The Gram staining of the
specimen provided preliminary identification
of the causative micro-organism in six cases; in
all of these, the staining revealed Gram positive
cocci. In 11 out of 17 vitreous specimens
Table 1 Patient characteristics
Patient No Male/female Age (years)
Visual acuity
At presentation After 3 months
1 F 75 Light perception Light perception
2 F 86 Counting fingers 0.25
3 F 75 Light perception Counting fingers
4 F 69 Counting fingers 1.0
5 F 83 Light perception Light perception
6 M 52 Hand movements 1.0
7 M 73 Light perception Counting fingers
8 V 82 Light perception Counting fingers
9 V 77 Hand movements 0.5
10 V 74 Counting fingers 0.9
11 M 83 Hand movements 0.8
12 M 82 Light perception 0.15
13 F 60 0.5 1.0
14 F 61 0.4 0.6
15 M 78 Light perception Counting fingers
16 F 84 Counting fingers 0.5
17 M 47 Hand movements 0.4
Table 2 Bacteriological findings
Patient No
Vancomycinl levels
(µg/ml)
Gentamicin levels
(µg/ml)
Time between drug
administration and
measurement (hours) Gram stain first biopsy
Bacterial culture
First biopsy Second biopsy
1 2.6 0.9 63 Gram positive cocci S epidermidis Sterile
2 12.0 1.4 66 No micro-organisms Sterile Sterile
3 10.8 — 68 Gram positive cocci S epidermidis Sterile
4 18.0 3.3 68 No micro-organisms S epidermidis Sterile
5 8.2 1.0 69 No micro-organisms Streptococcus sanguis Sterile
6 12.0 1.2 69 Gram positive cocci S epidermidis Sterile
7 15.5 — 71 No micro-organisms Sterile Sterile
8 6.3 1.9 71 Gram positive cocci S epidermidis Sterile
9 9.0 1.4 71 No micro-organisms Sterile Sterile
10 13.3 1.8 71 No micro-organisms S epidermidis Sterile
11 8.9 1.4 72 No micro-organisms S epidermidis Sterile
12 6.8 1.0 72 No micro-organisms Sterile Sterile
13 10.1 2.4 72 No micro-organisms Sterile Sterile
14 5.8 1.2 90 No micro-organisms S aureus Sterile
15 3.1 — 90 Gram positive cocci Streptococcus mitis Sterile
16 16.6 2.6 92 Gram positive cocci S epidermidis Sterile
17 4.6 — 93 No micro-organisms Sterile Sterile
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(65%), Gram positive bacteria were cultured,
predominantly coagulase negative staphyloco-
cci (73%), whereas in six specimens no bacte-
ria were cultured. All cultured micro-
organisms were susceptible to vancomycin.
In none of the cultures were Gram negative
micro-organisms isolated.
After 3 or 4 days a repeat vitreous specimen
was collected for culture in all patients. Gram
staining of the specimens failed to reveal
micro-organisms nor were any of the cultures
positive.
CONCENTRATIONS OF VANCOMYCIN AND
GENTAMICIN
Vancomycin levels (Fig 1)
In all 17 patients intravitreal vancomycin con-
centrations were measured. In 13 eyes the
repeat biopsy was performed after 3 days
(mean 70 (SD 2.7) hours) and in four eyes
after 4 days (mean 91 (1.7) hours). Vancomy-
cin concentrations varied between 2.6 and
18.0 µg/ml (mean 10.3 (4.1) µg/ml) after 3
days and between 3.1 and 16.6 µg/ml (mean
7.5 (6.2) µg/ml) after 4 days.
Gentamicin levels (Fig 2)
Measurements of intravitreal gentamicin levels
were performed in 13 patients. In 11 eyes the
second biopsy was performed after 3 days
(mean 70 (2.9) hours) and in two eyes after 4
days (mean 90 (1.5) hours). Concentrations
varied between 0.90 and 3.3 µg/ml (mean 1.6
(0.72) µg/ml) after 3 days and between 1.2 and
2.6 µg/ml (mean 1.9 (0.99) µg/ml) after 4 days.
Discussion
Most cases of postoperative endophthalmitis
are caused by Gram positive micro-
organisms.1–3 Vancomycin is therefore recom-
mended as a first choice for initial therapy of
suspected postoperative bacterial endo-
phthalmitis.1 3–6 The present study demon-
strates that vancomycin given at the dose of 0.2
mg intravitreally provides adequate empirical
antibiotic coverage in postoperative endoph-
thalmitis caused by Gram positive bacteria,
because it ensures the prolonged and continu-
ous exposure of the micro-organisms to the
antibiotic at a concentration well above the
MIC for the initial 3–4 days. At that time a sin-
gle repeat intravitreal injection of vancomycin
will maintain the concentration of the anti-
biotic well above the MIC for at least another 4
days. The antimicrobial eYcacy of the dosing
regimen was further confirmed by the finding
that in all of the 11 cases in which bacteria were
cultured from vitreous specimens at presenta-
tion, the repeat vitreous specimen failed to
yield bacterial growth.
Many ophthalmologists use a single dose of
1 mg intravitreal vancomycin to treat postop-
erative endophthalmitis following the recom-
mendations of the Endophthalmitis Vitrec-
tomy Study.1 The antimicrobial eVect of
glycopeptide antibiotics such as vancomycin
depends on the length of time its concentration
is maintained above the MIC.11 12 Thus, dosing
strategies should optimise the duration of drug
exposure to concentrations above the MIC,
rather than to aim at higher peak levels.9 10 In
this respect, adequate and safe antibiotic levels
can be better achieved by more frequent rather
than higher dosages. For vancomycin there are
valid concerns not to dose higher than
necessary. The commonly recommended dose
of 1 mg vancomycin is high because it results in
a vitreous concentration many times greater
than accepted serum and cerebrospinal fluid
concentrations in severe extraocular infections
such as endocarditis and meningitis. In these
infections, for reasons of toxicity, serum or
fluid concentrations of vancomycin are care-
fully kept between 5 and 20 µg/ml. These con-
centrations are of proved clinical eYcacy and
are about 10-fold higher than the MIC for
most Gram positive micro-organisms (MIC90
equal or less than 1–5 µg/ml).11 12 The intravit-
real injection of 1 mg of vancomycin should
result in a peak concentration of over 200–250
µg/ml in the vitreous and superficial retinal
structures. Given the time dependent pharma-
codynamic activity of vancomycin, with no fur-
ther gain in antimicrobial activity at MIC
above 5–10-fold,11 12 intravitreal dosing of van-
comycin at 50–200-fold of the MICs of the rel-
evant micro-organisms does not add to its anti-
microbial eYcacy but may increase the chance
of retinal toxicity. In fact, such concentrations
of vancomycin reached inadvertently in the
Figure 1 Intravitreal vancomycin concentrations.
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blood (for example, above 100 µg/ml) are gen-
erally considered an indication for immediate
dialysis and even exchange transfusion, to
avoid ototoxicity and nephrotoxicity.13–16
Though the rabbit eye apparently is not
damaged by vancomycin injected into the
vitreous at doses up to 2 mg, there is certainly
concern for retinal toxicity at high concentra-
tions of vancomycin injected into human
eyes.9 10
Although data have been published from
animal studies concerning the half life determi-
nation and elimination route of intravitreal
vancomycin,5 17–19 only one report of a series of
four patients is available on intravitreal vanco-
mycin concentrations over time in human
eyes.7 Aguilar et al estimated an intravitreal
vancomycin clearance with a half life of 25
hours in human phakic eyes based on experi-
ments in rabbit eyes in which inflammation
had no significant influence.17 Clearance in
pseudophakic eyes with an intact posterior
capsule is thought to be more similar to phakic
rather than to aphakic eyes.5 Using these data
and assuming the volume of the human
vitreous cavity to be approximately 4 ml, we
chose a dose regimen of 0.2 mg vancomycin
and a same dose repeat injection after 3–4
days.
By way of contrast, the antimicrobial eVect
of aminoglycosides such as gentamicin de-
pends on peak concentration at the site of
infection—that is, their activity is “concentra-
tion” rather than “time” dependent.20 If
toxicity allows, these drugs should be given less
frequently but at higher dosages.
Gentamicin has been widely used to treat
bacterial endophthalmitis because of its eVec-
tiveness against Gram negative bacteria,21–23
but because of reports of retinal toxicity in
patients with intravitreal doses between 0.10
and 0.40 mg24–26 many institutes replaced
gentamicin with other, presumably less toxic,
agents. In our treatment protocol a lower dose
of 0.05 mg gentamicin is added with the first
intravitreal injection to cover the Gram nega-
tive organisms not sensitive to vancomycin. For
this single use of intravitreal gentamicin our
aim was to reach an adequate peak level for
bacterial killing during the first 48 hours until
Gram stain or culture results exclude a Gram
negative organism. We estimated that a dose of
0.05 mg of gentamicin should be suYcient to
reach an adequate peak level of approximately
12.5 µg/ml and a minimum therapeutic level of
4 µg/ml during the first 2 days.27–30 In the rare
case of Gram negative endophthalmitis, we
would immediately inject intravitreal ceftazi-
dime in combination with intravenous ceftazi-
dime. Furthermore, the synergistic anti-
microbial activity of glycopeptides and
aminoglycosides against Gram positive bacte-
ria is a potential advantage in the treatment of
postoperative endophthalmitis caused by these
micro-organisms.5
In conclusion, our study demonstrates that
we succeed in reaching adequate intravitreal
antibiotic levels with our low dose regimen as
shown by direct concentration measurements
of vitreous samples and the sterile cultures
from all second biopsies. From these data, we
can extrapolate that the commonly used 1 mg
dose of vancomycin results in adequate anti-
biotic concentrations for over 1 week at the
expense of a higher than necessary concentra-
tion during the first 5 days. The potential risk
of retinotoxicity should then be weighed
against the possible complications of a second
intravitreal injection as in our regime.
Our series, however, is small and did not
contain very virulent organisms. Therefore
only further practice will show its clinical eVec-
tiveness in such patients. This study was
important in obtaining precise information on
vitreous vancomycin and gentamicin concen-
tration over time in patients with postoperative
endophthalmitis.
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